Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO Capital reaffirmed its Outperform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on December 17. The pharmaceutical company anticipates adjusted profit to be between $2.80 and $3 per share in the upcoming year. In comparison to the updated 2025 sales forecast of $62 billion, Pfizer’s revenue is anticipated to be essentially flat, coming between $59.5 billion and $62.5 billion. ...

SHANGHAI, CHINA - 2025/11/08: The Pfizer logo is presented at the 8th China International Import Expo. (Photo by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesPfizer (PFE) is encountering threats. Even the most prominent names aren't immune. Stocks can decline sharply without any warning – erasing months or years of gains in just a few weeks. History indicates that unexpected market fluctuations can affect any company, regardless of its dominance.Pfizer’s sh ...

Core Viewpoint - Pfizer is forecasting modest guidance for 2026 as it focuses on long-term investments in its pipeline to mitigate declining sales from Covid products and older drugs [1] Group 1: Financial Outlook - Pfizer expects adjusted profit for 2026 to be between $2.80 and $3 per share, slightly below analysts' consensus estimate of $3.05 per share [3] - Revenue is projected to be between $59.5 billion and $62.5 billion, which is largely flat compared to the 2025 sales guidance of $62 billion [4] - The company anticipates a decline of approximately $1.5 billion in sales from Covid vaccine and antiviral pill Paxlovid, projecting 2026 sales from these products to be around $5 billion [4] Group 2: Market Challenges - Pfizer is facing a projected $1.5 billion year-over-year drop in sales due to certain products losing market exclusivity, with increased competition impacting blockbuster drugs like Prevnar [5] - Patent expirations are expected to significantly affect revenues, with an estimated $17 billion impacted by expirations occurring primarily in 2026 and 2028 [6] Group 3: Strategic Investments - The company has made significant acquisitions, including a $10 billion deal for Metsera and a $43 billion acquisition of Seagen, to build new revenue streams [2] - However, the benefits from these investments are still distant, as Metsera's pipeline consists of drugs in early-stage development [3] Group 4: Cost Management - Pfizer has exceeded its cost-saving goals for 2025 and is targeting over $7 billion in cost cuts by 2027, expecting to deliver most of these savings by next year [8] - The guidance reflects costs associated with recent acquisitions, including Metsera [7] Group 5: Regulatory Environment - The company is navigating changes in U.S. vaccine policy, which has introduced uncertainty, particularly under Health and Human Services Secretary Robert F. Kennedy Jr. [9] - Pfizer's CEO stated that comments from the FDA regarding vaccines do not merit concern and will not alter the company's long-term investment strategy [10] Group 6: Pricing Strategy - Pfizer has entered a drug pricing deal that includes selling existing drugs to Medicaid patients at the lowest price offered in other developed nations, which will lead to price and margin compression in 2026 [11]

此外，辉瑞公司最畅销的血液稀释剂Eliquis的价格下调将于明年生效，此前该药被列入拜登时代的《通 胀削减法案》谈判名单。与此同时，辉瑞的关键药物，如肺炎疫苗Prevnar和心脏病治疗药物Vyndaqel， 正面临来自竞争对手的日益激烈的竞争。 这促使Bourla开始寻求收购机会，以帮助辉瑞公司拓展其药物研发管线。该公司最近在与诺和诺德 (NVO.US)的激烈竞购战中胜出，成功收购了肥胖症药物生产商Metsera。 辉瑞斥资100亿美元收购Metsera，使其在这个快速增长的领域获得了一系列极具潜力的新型肥胖症药 物，而此前辉瑞一直难以打入该领域。然而，Metsera的药物仍处于早期研发阶段，这意味着它们可能 还需要数年时间才能上市。 智通财经APP获悉，辉瑞(PFE.US)预测，随着该公司正努力通过一系列昂贵的收购来更新其热门药物产 品线，明年的销售增长将微乎其微甚至没有增长。辉瑞公司周二在一份声明中表示，预计2026年营收将 在595亿美元至625亿美元之间，与华尔街的预期大致相符。今年销售额预计为620亿美元，与该公司11 月初的指引范围一致。该公司预计明年调整后每股收益将位于2.80美元至3美元之间。 ...

Core Viewpoint - Pfizer is making a significant return to the GLP-1 drug market by acquiring the global rights to the oral small molecule GLP-1 receptor agonist YP05002 from Huayou Pharmaceutical for up to $20.85 billion, marking a record for early-stage Chinese innovative drug transactions [1][2] Group 1: Pfizer's Strategic Move - After three failed attempts in developing its own GLP-1 drugs, Pfizer's acquisition reflects its urgency to secure a position in the competitive GLP-1 market, especially against leaders like Novo Nordisk and Eli Lilly [1][4] - The deal includes an upfront payment of $150 million, with potential milestone payments of up to $1.935 billion and future sales royalties [1] - This acquisition follows Pfizer's recent $10 billion purchase of Metsera, indicating a strong commitment to the metabolic disease sector as a core growth area [1][8] Group 2: Challenges in GLP-1 Development - Pfizer has faced multiple setbacks in the GLP-1 space, including the termination of clinical development for Lotiglipron and Danuglipron due to safety concerns and adverse effects [4][7] - The company has nearly exhausted its pipeline in the GLP-1 area, with only one candidate remaining in the II phase, highlighting the need for external acquisitions to regain competitiveness [7][8] Group 3: Market Potential and Competitive Landscape - The global market for GLP-1 drugs is projected to reach $95 billion by 2030 and potentially $120 billion by 2035, emphasizing the importance of this market for Pfizer's future growth [7] - Pfizer's CEO has indicated that weight loss drugs could become a major product for the company, with expected annual sales of $10 billion [8] Group 4: Rationale for Choosing Huayou Pharmaceutical - YP05002 is a fully proprietary oral small molecule GLP-1 receptor agonist with demonstrated pharmacokinetic advantages in preclinical studies, making it a promising candidate [9][10] - Huayou Pharmaceutical's strong industrialization capabilities and established production credentials, including FDA certification, enhance the attractiveness of this acquisition [10][11] - The collaboration reflects a broader trend of Chinese innovative drugs entering international markets, showcasing the growing value of Chinese pharmaceutical R&D [11]

Group 1 - Pfizer Inc. is currently facing challenges as the entire pharmaceutical industry is experiencing a downturn, leading to a decline in stock performance despite being a historically strong company [1][2] - The stock has been trading around the $25 level, with shareholders currently satisfied with a 7% yield but little price appreciation, indicating a shift from growth to a more stable investment profile [2] - The company manufactures a range of medicines and vaccines across various therapeutic areas, including notable brands such as Comirnaty, Paxlovid, and Eliquis, which contribute to its cash flow and support its dividend [2] Group 2 - There is a belief that certain AI stocks may present greater upside potential compared to Pfizer, suggesting a competitive landscape for investment opportunities [2]

Core Insights - Pfizer reported third-quarter 2025 adjusted earnings per share (EPS) of 87 cents, exceeding the Zacks Consensus Estimate of 66 cents, but reflecting an 18% decline year over year [1] - Total revenues were $16.7 billion, down 6% from the previous year, primarily due to decreased sales from COVID-19 products, Comirnaty and Paxlovid, although it slightly beat the Zacks Consensus Estimate of $16.60 billion [2] Revenue Breakdown - International revenues increased by 2% on an operational basis to $5.96 billion, while U.S. revenues fell by 11% to $10.69 billion [2] - The Primary Care segment saw a 16% operational decline to $7.65 billion, while Specialty Care recorded a 1% increase to $4.41 billion, and Oncology sales rose by 4% to $4.25 billion [3] Product Performance - Eliquis sales rose by 22% to $2.02 billion, surpassing estimates, despite some price erosion in international markets [4] - Global Prevnar family revenues decreased by 4% to $1.74 billion, missing estimates, with U.S. sales down 12% but international sales up 17% [5] - Comirnaty sales were $1.15 billion, down 20% year over year, but still beat estimates [6] - Paxlovid revenues fell by 55% to $1.23 billion due to lower infection rates, although it exceeded estimates [7] - New product Abrysvo recorded sales of $279 million, down 22% year over year due to limited vaccination recommendations [8] Specialty Care and Oncology - Vyndaqel family revenues rose by 7% to $1.59 billion, driven by increased diagnosis and treatment rates, but missed estimates [9][10] - Ibrance revenues declined by 5% to $1.06 billion, beating estimates [11] - Among ADCs from the Seagen acquisition, Adcetris sales fell by 20% to $215 million, while Padcev rose by 13% to $464 million, missing estimates [12] Guidance and Outlook - Pfizer reaffirmed its 2025 revenue guidance of $61.0 billion to $64.0 billion and raised its adjusted EPS guidance to $3.00-$3.15 from $2.90-$3.10 [14] - Research and development expenses are projected to be between $10.0 billion and $11.0 billion, with an adjusted tax rate expected around 11% [15] Competitive Landscape - Pfizer is engaged in a competitive acquisition battle with Novo Nordisk for Metsera, with Pfizer's offer at approximately $4.9 billion and Novo Nordisk's unsolicited proposal at around $6.5 billion [18][19] - Pfizer has also signed a drug pricing agreement with the Trump administration, aiming to cut prescription drug prices in exchange for tariff exemptions [20]

Financial Data and Key Metrics Changes - For Q3 2025, the company recorded revenues of $16.7 billion, a decrease of 7% operationally compared to the same period last year, primarily driven by a decline in COVID products [23] - Reported diluted earnings per share (EPS) was $0.62, while adjusted diluted EPS was $0.87, exceeding expectations due to strong gross margin and cost management performance [24] - Adjusted gross margin for the quarter was approximately 76%, reflecting product mix and strong cost management [25] Business Line Data and Key Metrics Changes - Non-COVID product performance was solid, growing 4% operationally compared to the same period last year, with significant contributions from Eliquis, the Vyndaqel family, and Nurtec [23][24] - The Vyndaqel family achieved 7% year-over-year global operational growth, while Padcev saw 13% year-over-year global operational growth [14][15] - The company’s recently launched and acquired products generated $7.3 billion in revenue, growing approximately 9% operationally year-over-year [24] Market Data and Key Metrics Changes - In international markets, the Vyndaqel family achieved 40% growth in total patients on treatment, while Nurtec led the oral CGRP class in primary care penetration in the U.S. [15] - The Prevnar family of vaccines saw 17% year-over-year international operational growth, with strong performance in pediatric pneumococcal vaccination [16] - The company expects the lung cancer market to reach approximately $70 billion by 2023, with significant growth potential in its lung cancer portfolio [12] Company Strategy and Development Direction - The company is focused on strategic investments in innovation and growth, highlighted by the proposed acquisition of MedSera and the licensing agreement with 3SBio [6][8] - The company aims to enhance its R&D pipeline and commercial capabilities, particularly in the high-growth therapeutic area of obesity [8] - The recent agreement with the U.S. government aims to lower prescription drug costs while allowing the company to invest in U.S. manufacturing [7][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver value for patients and shareholders, despite challenges in the COVID product line [5] - The company raised its adjusted diluted EPS guidance for the full year 2025, reflecting strong performance and improved cost structure [33] - Management noted that the agreement with the U.S. government will not impact 2025 guidance but may affect the 2026 financial outlook [32] Other Important Information - The company expects to achieve $1.5 billion in savings from its manufacturing optimization program by the end of 2027 [26] - The gross leverage at the end of Q3 was approximately 2.7 times, with expectations to return to target levels post-MedSera acquisition [31] - The company plans to provide guidance for 2026 by the end of the year [35] Q&A Session Summary Question: Insights on Vyndamax performance amid competition - Management acknowledged new competition but emphasized Vyndamax's unique benefits and strong market access, noting that volume growth was offset by gross-to-net headwinds [41][42] Question: Legal process regarding MedSera acquisition - Management stated that it is difficult to comment on the timing of legal proceedings but reiterated their belief that Novo's acquisition attempt is anti-competitive [48][50] Question: Plans if MedSera acquisition does not proceed - Management confirmed ongoing efforts to identify potential acquisition candidates across therapeutic areas, regardless of the MedSera outcome [52][54] Question: Dynamics of Paxlovid pricing - Management clarified that there were no significant changes in Paxlovid pricing, attributing variations to channel mix rather than material price changes [74] Question: Guidance on COVID-19 sales for the year - Management indicated that achieving the previously stated $9 billion in COVID sales is uncertain, depending on potential future COVID waves [87][90] Question: Pricing strategy for GLP-1 medicines - Management acknowledged that competition is driving prices down and that their calculations for the MedSera acquisition took this into account [94] Question: Delay in initiation of pivotal trial for pneumococcal vaccine - Management explained that the delay is due to ongoing discussions with the FDA regarding study designs and endpoints, with plans to align pediatric and adult studies [100]

Financial Data and Key Metrics Changes - For Q3 2025, the company recorded revenues of $16.7 billion, a decrease of 7% operationally compared to the same period last year, primarily driven by a decline in COVID products, particularly Paxlovid [20][21] - Reported diluted earnings per share (EPS) was $0.62, while adjusted diluted EPS was $0.87, exceeding expectations due to strong gross margin and cost management performance [21][24] - Adjusted gross margin for Q3 was approximately 76%, reflecting product mix and strong cost management within the manufacturing footprint [22] Business Line Data and Key Metrics Changes - The non-COVID product performance was solid, growing 4% operationally compared to the same period last year, with strong contributions from Eliquis, the Vyndaqel family, and Nurtec [20][21] - The Vyndaqel family achieved 7% year-over-year global operational growth, while Padcev saw 13% year-over-year global operational growth [12][13] - The vaccines portfolio, particularly the Prevnar family, achieved 17% year-over-year international operational growth [15] Market Data and Key Metrics Changes - In international markets, the company achieved 40% growth in total patients on treatment for the Vyndaqel family [12] - The U.S. market saw double-digit demand growth for the Vyndaqel family, reflecting strong diagnostic efforts and broad access [12][13] - The company experienced a year-over-year decline in the U.S. for Prevnar 20, attributed to delayed government bulk orders [15][16] Company Strategy and Development Direction - The company is focused on strategic investments in future innovation and growth, highlighted by the proposed acquisition of MedSera and the licensing agreement with 3SBio [4][5] - The company aims to enhance its R&D pipeline and commercial capabilities, particularly in the cardiometabolic area and oncology [6][8] - The recent agreement with the U.S. government is expected to lower prescription drug costs and provide clarity for future investments [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to deliver value for patients and shareholders, despite challenges in the COVID product line [4][18] - The company raised its adjusted diluted EPS guidance for the full year 2025, reflecting strong performance and improved cost structure [30] - Management noted that the agreement with the U.S. government will not impact 2025 guidance but may have a diluted effect on 2026 financial outlook [29] Other Important Information - The company expects to achieve $1.5 billion in savings from the manufacturing optimization program by the end of 2027 [23][25] - The MedSera acquisition is expected to be funded through a mix of available cash and debt, with anticipated dilution to adjusted EPS in 2026 [26][27] - The company plans to continue investing in R&D and business development to enhance its product portfolio and pipeline [30] Q&A Session Summary Question: Comments on Vyndamax performance amid competition - Management acknowledged new competition but emphasized Vyndamax's unique benefits and strong market share, despite some gross-to-net headwinds impacting net sales [32][35] Question: Legal process regarding MedSera acquisition - Management stated that it is difficult to comment on the timing of legal proceedings but reiterated the belief that Novo's acquisition attempt is anti-competitive [38][39] Question: Plans if MedSera acquisition does not proceed - Management indicated that the company has significant resources and will continue to pursue business development opportunities across therapeutic areas [39][40] Question: Impact of manufacturing investments under the MFN agreement - Management highlighted the importance of both manufacturing investments and operational cost efficiencies, indicating that both will be prioritized [42][43] Question: Guidance for total COVID-19 sales - Management acknowledged the uncertainty in COVID-19 sales but reiterated confidence in achieving the overall revenue guidance range [49] Question: Pricing dynamics for GLP-1 medications - Management acknowledged that competition may drive prices down but indicated that their calculations for the MedSera acquisition took potential pricing declines into account [51] Question: Delay in initiation of pivotal trial for pneumococcal program - Management explained that the timing of the trial initiation is contingent on FDA alignment and that they are coordinating pediatric and adult studies [52][53]

Core Viewpoint - Pfizer (PFE.US) reported better-than-expected Q3 2025 results and raised its full-year earnings forecast, attributing the performance to ongoing cost-cutting measures that offset sales growth slowdown, which also provided funding for its acquisition of weight-loss startup Metsera (MTSR.US) [1] Financial Performance - Q3 2025 revenue decreased by 6% year-over-year to $16.654 billion, surpassing analyst expectations of $16.5 billion; adjusted net income was $4.949 billion, down 18% year-over-year; adjusted diluted EPS was $0.87, exceeding the expected $0.64 [1][2] - For the first nine months of 2025, total revenues were $45.022 billion, a 2% decline from $45.864 billion in 2024; reported net income increased by 24% to $9.419 billion [2] Business Segment Performance - The Global Biopharmaceuticals Business (Biopharma) saw a 6% decline in Q3 revenue to $16.310 billion; Pfizer CentreOne revenue increased by 21% to $344 million, while Pfizer Ignite revenue plummeted by 99% to $25 million [3] - Key drug sales showed mixed results: Comirnaty (COVID-19 vaccine) sales fell 19% to $1.151 billion; Prevnar (pneumonia vaccine) sales decreased 3% to $1.742 billion; Vyndaqel (heart failure treatment) sales grew 10% to $1.591 billion, but fell short of the $1.68 billion forecast [4] Future Outlook - Pfizer expects full-year 2025 revenue to be between $61 billion and $64 billion, with adjusted diluted EPS projected between $3.00 and $3.15, an increase from the previous forecast of $2.90 to $3.10 [5][4] Acquisition and Legal Actions - Pfizer announced a cash acquisition of Metsera at $47.50 per share, valuing the deal at approximately $4.9 billion, with potential additional payments bringing the total to $7.3 billion if certain R&D milestones are met [6] - Novo Nordisk (NVO.US) made a competing cash offer of $56.50 per share for Metsera, prompting Pfizer to file antitrust lawsuits against both Novo Nordisk and Metsera, claiming the acquisition would harm competition in the obesity treatment market [7]